BioStem Technologies, Inc. (BSEM)
OTCMKTS · Delayed Price · Currency is USD
6.25
-4.13 (-39.79%)
Aug 15, 2025, 9:38 AM EDT
BioStem Technologies Revenue
BioStem Technologies had revenue of $72.53M in the quarter ending March 31, 2025, with 73.08% growth. This brings the company's revenue in the last twelve months to $332.45M, up 473.06% year-over-year. In the year 2024, BioStem Technologies had annual revenue of $301.83M with 1,708.93% growth.
Revenue (ttm)
332.45M
Revenue Growth
+473.06%
P/S Ratio
0.52
Revenue / Employee
10.07M
Employees
33
Market Cap
173.74M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 301.83M | 285.14M | 1,708.93% |
Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
Dec 31, 2017 | 313.45K | -293.78K | -48.38% |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
BioStem Technologies News
- 13 hours ago - BioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 17 hours ago - BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results - GlobeNewsWire
- 17 hours ago - BioStem Technologies Appoints Brandon Poe as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes - GlobeNewsWire
- 5 weeks ago - BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET - GlobeNewsWire
- 2 months ago - BioStem Technologies: Huge Growth, Poised To Help Wound Care Field - Seeking Alpha
- 3 months ago - Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist - GlobeNewsWire
- 3 months ago - BioStem Technologies, Inc. (BSEM) Q1 2025 Earnings Call Transcript - Seeking Alpha